
News|Articles|March 1, 2005
Exenatide: A novel incretin mimetic hormone for the treatment of type 2 diabetes
A number of clinical approaches are utilized in managing the overlapping aspects of poor glycemic control in patients with type 2 diabetes. Exenatide (Amylin/Lilly), a novel drug in a new medication class known as the incretin mimetic agents, offers a new mechanism to achieve glycemic control.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
2025 FDA added indications to dermatologic medications
2
Immune system targets single beta cells before Type 1 diabetes symptoms show
3
Jascayd gets second FDA approval, this time for progressive pulmonary fibrosis
4
Winter exposes how closely eczema, asthma and allergies are linked
5

















































